M. S.-Kh. Sozaeva
M. S.-Kh. Sozaeva has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Dmitrij Alekseevitch Sychev
Petrovsky National Research Centre of Surgery; Russian Medical Academy of Continuous Professional Education
3 shared publications - L. Z. Bolieva
North Ossetian State Medical Academy
3 shared publications - Sherzod Pardaboevich Abdullaev
Petrovsky National Research Center of Surgery, Moscow 119435, Russia
3 shared publications - Anastasiya A. Kachanova
Russian Medical Academy of Continuous Professional Education
2 shared publications - Elena A. Grishina
Bashkir State Medical University
2 shared publications - Karin Badavievich Mirzaev
Petrovsky National Research Center of Surgery, Moscow 119435, Russia
2 shared publications
Latest Publications
- Open Access
- 7 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (6) , 420-430
Prevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus
Drug sensitivity to, in particular to favipiravir, may vary among representatives of different ethnic groups. Studies have previously shown that carrying certain variants of the AOX1 and CYP1A2 genes may be associated with an increased incidence of adverse reactions with patients having COVID-19 and taking favipiravir. This work is devoted to studying the prevalence of mutant variants rs55754655 and rs10931910 of the AOX1 gene and rs762551 of the CYP1A2 gene in various ethnic groups of the North Caucasus.The aim. To characterize the distribution structure of AOX1 (rs55754655 and rs10931910) and CYP1A2 (rs762551) variants among the peoples of the North Caucasus (Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins).Materials and methods. The frequency of distribution of AOX1 and CYP1A2 gene variants was studied among 897 conditionally healthy volunteers (362 men — 40.4% and 535 women — 59.6%; average age — 34.6±6.3%), from 8 ethnic groups of the North Caucasus: Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins (n=100 for each), as well as 97 Russians (reference group).Results. As a result of the analysis, a significant difference was found in the allele frequencies for the rs10931910 AOX1 genetic polymorphism between Balkars and Russians (p p p CYP1A2 gene were found in the comparative analysis of ethnic groups with the comparison group.Conclusion. Significant differences were revealed in the frequency of AOX1 polymorphisms (rs10931910, rs55754655) in the peoples of the North Caucasus relative to the Russian population. The largest deviations were recorded in Dargins: a decrease in the frequency of the minor allele rs10931910 to 28.5% (p p=0.0105). The results may be useful for optimizing therapy with medicines that are AOX1 substrates, which include favipiravir, used to treat patients with COVID-19.
- 7 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (6) , 420-430
Open AccessPrevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus
Drug sensitivity to, in particular to favipiravir, may vary among representatives of different ethnic groups. Studies have previously shown that carrying certain variants of the AOX1 and CYP1A2 genes may be associated with an increased incidence of adverse reactions with patients having COVID-19 and taking favipiravir. This work is devoted to studying the prevalence of mutant variants rs55754655 and rs10931910 of the AOX1 gene and rs762551 of the CYP1A2 gene in various ethnic groups of the North Caucasus.The aim. To characterize the distribution structure of AOX1 (rs55754655 and rs10931910) and CYP1A2 (rs762551) variants among the peoples of the North Caucasus (Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins).Materials and methods. The frequency of distribution of AOX1 and CYP1A2 gene variants was studied among 897 conditionally healthy volunteers (362 men — 40.4% and 535 women — 59.6%; average age — 34.6±6.3%), from 8 ethnic groups of the North Caucasus: Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins (n=100 for each), as well as 97 Russians (reference group).Results. As a result of the analysis, a significant difference was found in the allele frequencies for the rs10931910 AOX1 genetic polymorphism between Balkars and Russians (p p p CYP1A2 gene were found in the comparative analysis of ethnic groups with the comparison group.Conclusion. Significant differences were revealed in the frequency of AOX1 polymorphisms (rs10931910, rs55754655) in the peoples of the North Caucasus relative to the Russian population. The largest deviations were recorded in Dargins: a decrease in the frequency of the minor allele rs10931910 to 28.5% (p p=0.0105). The results may be useful for optimizing therapy with medicines that are AOX1 substrates, which include favipiravir, used to treat patients with COVID-19.
- Open Access
- 19 February 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (1) , 60-67
Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2
The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080), PTGS1 (rs10306135), PTGS1 (rs12353214) and PTGS2 (rs20417) among residents of the North Caucasus.Patients and methods. The study involved 676 volunteers from Russian, Balkar, Kabardian and Ossetian ethnic groups. Carriage of polymorphic markers CYP2C8, PTGS1 and PTGS2 was determined using real-time polymerase chain reaction.Results and discussion. There were no significant differences between the groups in the rs10509681 and rs11572080 variants of the CYP2C8 gene. In all groups, the carriage of a combination of CYP2C8 and CYP2C9 alleles, encoding the phenotype of normal metabolizers, prevailed with a frequency of about 75% or more. The rs10306135 variant of the PTGS1 gene was found in 5.9% of Russians, 1.1% of Balkars, 5.3% of Kabardians, and 10.6% of Ossetians; variant rs12353214 – in 19.1; 9.4; 10.8 and 9.2%, rs20417 polymorphism of the PTGS2 gene in 0.4; 5; 2.8 and 3.1% respectively.Conclusion. The data obtained can be used to develop a more rational approach to the prescription of NSAIDs, taking into account the genetic characteristics of the local population in ethnic regions.
- 19 February 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (1) , 60-67
Open AccessStructure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2
The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080), PTGS1 (rs10306135), PTGS1 (rs12353214) and PTGS2 (rs20417) among residents of the North Caucasus.Patients and methods. The study involved 676 volunteers from Russian, Balkar, Kabardian and Ossetian ethnic groups. Carriage of polymorphic markers CYP2C8, PTGS1 and PTGS2 was determined using real-time polymerase chain reaction.Results and discussion. There were no significant differences between the groups in the rs10509681 and rs11572080 variants of the CYP2C8 gene. In all groups, the carriage of a combination of CYP2C8 and CYP2C9 alleles, encoding the phenotype of normal metabolizers, prevailed with a frequency of about 75% or more. The rs10306135 variant of the PTGS1 gene was found in 5.9% of Russians, 1.1% of Balkars, 5.3% of Kabardians, and 10.6% of Ossetians; variant rs12353214 – in 19.1; 9.4; 10.8 and 9.2%, rs20417 polymorphism of the PTGS2 gene in 0.4; 5; 2.8 and 3.1% respectively.Conclusion. The data obtained can be used to develop a more rational approach to the prescription of NSAIDs, taking into account the genetic characteristics of the local population in ethnic regions.
- Open Access
- 3 September 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (8) , 43-51
Analysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation
Aim. To study the peculiarities of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation. Materials and methods. The study included 1446 conditionally healthy volunteers from 9 ethnic groups. Carriage of polymorphic TPMT and DPYD gene markers was detected by the Real-Time PCR (polymerase chain reaction) method. Results. In all ethnic groups, the distribution of genotypes and alleles matched the equilibrium of Hardy-Weinberg. TPMT*3A (rs1800460) and TPMT*3C (rs1142345) were observed in heterozygous state in all investigated ethnic groups. In the Kabardinian group (n=204) the frequency of the TPMT*3A minor allele (MAF, %) was 2.94%; Balkars (n=200) 1.25%; Ossetians (n=239) 1.67%; Chuvashes (n=238) 1.89%: Mari (n=206) 1.21%; Tatars (n=141) 1.77%; Russians (n=134) 4.85%. The frequency of the TPMT*3C minor allele (MAF, %) in the Kabardinian group (n=204) MAF was 4.90%; Balkars (n=200) 1. 75%; Buryats (n=114) 0.44%; Ossetians (n=239) 1.88%; Chuvashes (n=238) 1.68%: Mari (n=206) 1.21%; Tatars (n=141) 1.42%; Russians (n=134) 4.48%. The results of the analysis of DPYD*2A polymorphism (rs3918290) demonstrated ethnic peculiarities of distribution. In the heterozygous state it was found only in the groups of Kabardins (n=204, MAF 1.22%), Balkars (n=200, MAF 2.00%), and Ossetians (n=239, MAF 0.63%). Conclusion. The results obtained in the study will be useful for developing personalized algorithms of antitumor therapy in cancer practice, including those aimed at increasing the safety of chemotherapy.
- 3 September 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (8) , 43-51
Open AccessAnalysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation
Aim. To study the peculiarities of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation. Materials and methods. The study included 1446 conditionally healthy volunteers from 9 ethnic groups. Carriage of polymorphic TPMT and DPYD gene markers was detected by the Real-Time PCR (polymerase chain reaction) method. Results. In all ethnic groups, the distribution of genotypes and alleles matched the equilibrium of Hardy-Weinberg. TPMT*3A (rs1800460) and TPMT*3C (rs1142345) were observed in heterozygous state in all investigated ethnic groups. In the Kabardinian group (n=204) the frequency of the TPMT*3A minor allele (MAF, %) was 2.94%; Balkars (n=200) 1.25%; Ossetians (n=239) 1.67%; Chuvashes (n=238) 1.89%: Mari (n=206) 1.21%; Tatars (n=141) 1.77%; Russians (n=134) 4.85%. The frequency of the TPMT*3C minor allele (MAF, %) in the Kabardinian group (n=204) MAF was 4.90%; Balkars (n=200) 1. 75%; Buryats (n=114) 0.44%; Ossetians (n=239) 1.88%; Chuvashes (n=238) 1.68%: Mari (n=206) 1.21%; Tatars (n=141) 1.42%; Russians (n=134) 4.48%. The results of the analysis of DPYD*2A polymorphism (rs3918290) demonstrated ethnic peculiarities of distribution. In the heterozygous state it was found only in the groups of Kabardins (n=204, MAF 1.22%), Balkars (n=200, MAF 2.00%), and Ossetians (n=239, MAF 0.63%). Conclusion. The results obtained in the study will be useful for developing personalized algorithms of antitumor therapy in cancer practice, including those aimed at increasing the safety of chemotherapy.